Brainstorm Cell Therapeutics (BCLI) Tops Q1 EPS by 15c

Brainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q1 EPS of ($0.10), $0.15 better than the analyst estimate of ($0.25).

For earnings history and earnings-related data on Brainstorm Cell Therapeutics (BCLI) click here.

You May Also Be Interested In

• Royal Caribbean to acquire 50% stake in Sandals Resorts for $3 billion
• AutoZone (AZO) Tops Q4 EPS by $1.76, Misses on Revenue
• Ennis (EBF) Misses Q2 EPS by 2c